Ulisse Biomed has a new board of directors, Lo Priore chairman and Basile CEO

(Alliance News) - Ulisse Biomed Spa announced Monday that shareholders have appointed the board, which will be chaired by Stefano Lo Priore.

In addition to Lo Priore, Nicola Basile, Bruna Marini, Carlo Giuseppe Montenovesi, and Cristina Sbaizero join the board. The board will serve until the approval of the 2026 accounts and will earn a total of EUR85,000. Basile was then appointed managing director.

On the other hand, Alberto Maria Camillotti, Ignazio Pellecchia, Massimo Fulvio Campanelli, Valentina De Luca, and Giovanni Licari join the board of auditors.

Matteo Petti said, "In recent years, I have had the honor of leading UBM through a period of significant changes and challenges. During my tenure, we have worked tirelessly to develop and implement an ambitious and innovative business plan aimed at sustainable growth and positioning the company for future success. I believe that my managerial contribution has come to an end with the successful outcome of the recently completed reverse-takeover transaction, and that my resignation will enable the new board of directors to successfully advance the business plan and lead the company to new heights."

"My lateral step is, therefore, constructive and in full passionate trust and participation of the UBM-Hyris project in which I firmly believe. I would like on this occasion to express my personal thanks to all the members of the corporate bodies and employees of the UBM group with whom I have shared an exciting journey of personal growth and a truly unique entrepreneurial development experience."

Stefano Lo Priore said, "On behalf of the board of directors and also personally, I sincerely thank Matteo Petti for guiding UBM to this operation and for its successful completion. I wish him the best in his professional future. Equally, I thank the shareholders' meeting for trusting me to lead this ambitious industrial project. I welcome the members of the new board of directors, with whom we will work together in the near future to achieve the goals of this integrated and distinctive project."

Ulysses Biomed's stock closed Monday down 1.3 percent at EUR1.55 per share.

By Giuseppe Fabio Ciccomascolo, Alliance News senior reporter

Comments and questions to [e-mail]

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.